Archive: 2019

Investors chronicle: 'IXICO upgrades guidance again'

Published on investors chronicle: 15th October Author: Simon Thompson The world’s largest biopharmaceutical companies are investing huge sums of money in the field of neurology to target therapies for diseases affecting the central nervous system including Huntington’s, Alzheimer’s and Parkinson’s disease.

Investors chronicle: 'Profit from artificial intelligence in neuroscience'

Published on investors chronicle: 22nd July, 2019 Author: Simon Thompson IXICO may be a small-cap London-based company well under the radar of investors, but it is highly regarded by pharmaceutical and biotechnology companies and huge corporations are increasingly awarding the company new contracts.